Back to Search
Start Over
Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
- Source :
- Neuropharmacology. 190:108553
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Childhood Absence Epilepsy (CAE) accounts for approximately 10% of all pediatric epilepsies. Current treatments for CAE are ineffective in approximately 1/3 of patients and can be associated with severe side effects such as hepatotoxicity. Certain cannabinoids, such as cannabidiol (CBD), have shown promise in the treatment of pediatric epilepsies. However, CBD remains limited or prohibited in many jurisdictions, and has not been shown to have efficacy in CAE. Modulation of the type 1 cannabinoid receptor (CB1R) may provide more desirable pharmacological treatments. Genetic Absence Epilepsy Rats from Strasbourg (GAERS) model many aspects of CAE, including cortical spike and wave discharges (SWDs). We have recently demonstrated that Δ9-tetrahydrocannabinol (THC) increases SWDs in GAERS whereas CBD decreases these events. Here, we characterized aspects of the endocannabinoid system in brain areas relevant to seizures in GAERS and tested whether positive allosteric modulators (PAMs) of CB1R reduced SWDs. Both female and male GAERS had reduced (>50%) expression of CB1R and elevated levels of the endocannabinoid 2-AG in cortex compared to non-epileptic controls (NEC). We then administered the CB1R PAMs GAT211 and GAT229 to GAERS implanted with cortical electrodes. Systemic administration of GAT211 to male GAERS reduced SWDs by 40%. Systemic GAT229 administration reduced SWDs in female and male GAERS. Intracerebral infusion of GAT229 into the cortex of male GAERS reduced SWDs by >60% in a CB1R-dependent manner that was blocked by SR141716A. Together, these experiments identify altered endocannabinoid tone in GAERS and suggest that CB1R PAMs should be explored for treatment of absence seizures.
- Subjects :
- Male
0301 basic medicine
Indoles
Cannabinoid receptor
medicine.medical_treatment
Arachidonic Acids
Pharmacology
Glycerides
03 medical and health sciences
Cellular and Molecular Neuroscience
Epilepsy
0302 clinical medicine
Childhood absence epilepsy
Allosteric Regulation
Receptor, Cannabinoid, CB1
Animals
Medicine
Cannabinoid Receptor Agonists
Cerebral Cortex
business.industry
Spike-and-wave
medicine.disease
Brain Waves
Endocannabinoid system
Rats
3. Good health
Disease Models, Animal
030104 developmental biology
Epilepsy, Absence
Systemic administration
Female
Cannabinoid
business
Cannabidiol
030217 neurology & neurosurgery
Endocannabinoids
medicine.drug
Subjects
Details
- ISSN :
- 00283908
- Volume :
- 190
- Database :
- OpenAIRE
- Journal :
- Neuropharmacology
- Accession number :
- edsair.doi.dedup.....fb22dfe549059f8e8d79eaaa08774db7
- Full Text :
- https://doi.org/10.1016/j.neuropharm.2021.108553